Klebsiella, Enterobacter, and Serratia are closely related normal intestinal flora that rarely cause disease in normal hosts.

Infections with Klebsiella, Enterobacter, and Serratia are usually hospital-acquired and occur mainly in patients with diminished resistance. Usually, Klebsiella, Enterobacter, and Serratia cause a wide variety of infections, including bacteremia, surgical site infections, intravascular catheter infections, and respiratory or urinary tract infections that manifest as pneumonia, cystitis, or pyelitis and that may progress to lung abscess, empyema, and septicemia. Klebsiella pneumonia, a rare and severe disease with dark brown or red currant–jelly sputum, lung abscess formation, and empyema, is most common among diabetics and alcoholics. Serratia, particularly S. marcescens, has greater affinity for the urinary tract. Enterobacter can cause otitis media, cellulitis, and neonatal sepsis.

Treatment is with 3rd-generation cephalosporins, cefepimeSome Trade Names
MAXIPIME
Click for Drug Monograph
, carbapenems, fluoroquinolones, piperacillin/tazobactamSome Trade Names
ZOSYN

, or aminoglycosides. However, because some isolates are resistant to multiple antibiotics, susceptibility testing is essential. Klebsiella strains that produce extended-spectrum β-lactamase (ESBL) may develop resistance to cephalosporins during treatment, particularly with ceftazidimeSome Trade Names
FORTAZ
TAZICEF
Click for Drug Monograph
. Enterobacter strains may be resistant to most β-lactam antibiotics, including 3rd-generation cephalosporins; the β-lactamase enzyme they produce is not inhibited by the usual β-lactamase inhibitors (clavulanate, tazobactam, sulbactam). However, these Enterobacter strains may be susceptible to carbapenems (eg, imipenem, meropenemSome Trade Names
MERREM
Click for Drug Monograph
, ertapenemSome Trade Names
INVANZ
Click for Drug Monograph
).

Last full review/revision August 2009 by Burke A. Cunha, MD

Content last modified February 2012